ALL
-
-
May 13, 2022 performance
-
-
performance
-
Consolidated Financial Results for the Fiscal Year Ended March 31, 2022(570 KB)
-
-
May 13, 2022 corporate
-
-
corporate
-
Notice Regarding Decision on the Candidates for Directors(115 KB)
-
-
Apr 18, 2022 performance
-
-
performance
-
Notice Regarding Revision of the Full-year Earnings Forecasts for the Fiscal Year Ended March 2022(120 KB)
-
-
Mar 30, 2022 other
-
-
other
-
Notice Regarding Cease and Desist Order and Surcharge Payment Order from the Japan Fair Trade Commission(70 KB)
-
-
Mar 10, 2022 M&A/partnership
-
-
M&A/partnership
-
Notice Regarding Share Acquisition of AYM HD KK(130 KB)
-
-
Feb 09, 2022 performance
-
-
performance
-
Consolidated Financial Results for the Nine Months Ended December 31, 2021(474 KB)
-
-
Jan 26, 2022 product/service
-
-
product/service
-
Notice Regarding Approval of Partial Amendments to Indications and Usage of Ezetimibe Tablets 10mg “KMP” for KYOSOMIRAI PHARMA(118 KB)
-
-
Jan 07, 2022 M&A/partnership
-
-
M&A/partnership
-
Notice Regarding Agreement for Business Alliance with Cellusion Inc.(75 KB)
-
-
Dec 10, 2021 M&A/partnership
-
-
M&A/partnership
-
Notice Regarding Agreement for Business Alliance with CellGenTech, Inc.(70 KB)
-
-
Dec 10, 2021 product/service
-
-
product/service
-
Notice Regarding Launch of 3 Ingredients / 5 Products of Generic Drugs for KYOSOMIRAI PHARMA(118 KB)
-
-
Nov 12, 2021 performance
-
-
performance
-
Summary of Consolidated Financial Results for the First Half of Fiscal Year Ending March 2022(399 KB)
-
-
Nov 09, 2021 other
-
-
other
-
Notice regarding Onsite Inspection at a Consolidated Subsidiary by the Japan Fair Trade Commission(109 KB)
-
-
Oct 27, 2021 product/service
-
-
product/service
-
Notice Regarding Approval of Partial Amendments to Indications, Dosage and Administration of Imatinib Tablets 100mg “KMP” for KYOSOMIRAI PHARMA(103 KB)
-
-
Oct 15, 2021 other
-
-
other
-
Notice Regarding Application for Selection of “Prime Market” in Tokyo Stock Exchange New Market Segments(76 KB)
